

Clarification of References to Medication Adherence Scale


The authors of the Trends From the Field article, “Health Literacy, Preventive Health Screening, and Medication Adherence Behaviors of Older African Americans at a PCMH,” published in the September 2018 issue of *The American Journal of Managed Care*[®]; have issued this statement to clarify and correct any misunderstanding caused by the abbreviations used for describing the medication adherence scale mentioned across various segments (Abstract, Methods, Results, Discussion, and Table 2) of the article.¹

The medication adherence scale used in the study for the authors’ article was the Self-reported Medication-taking Scale published in

1986 by Morisky et al.² The authors inadvertently referred to the scale as the Morisky Medication Adherence Scale and abbreviated it as MMAS. Any confusion from the inadvertent reference to the Morisky Medication Adherence Scale, as well as the use of the acronym MMAS to refer to the Self-reported Medication-taking Scale, was unintentional. ■

REFERENCES


1. Aranha ANF, Patel PJ. Health literacy, preventive health screening, and medication adherence behaviors of older African Americans at a PCMH. *Am J Manag Care*. 2018;24(9):428-432.
2. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. *Med Care*. 1986;24(1):67-74.



THE CENTER FOR
BIOSIMILARS[®]


Health economics experts.
Managed care professionals.
Key clinical specialists.

Join The Center for Biosimilars[®] network to gain access to industry leading insights and engage with your peers.




PEER EXCHANGE[™]

Our Peer Exchange[™] program provides a multistakeholder perspective on important issues that providers, pharmacists, payers, and patients grapple with as they step into the world of biosimilars.




NEWS

We provide the most up-to-date clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.




CONFERENCE COVERAGE

From clinical developments to policy concerns, we provide coverage of the top conferences on biologics and biosimilars.



The Center for Biosimilars[®] was cited in United States Senate testimony on prices and out-of-pocket costs for rheumatoid arthritis drugs. The resource also discusses the current landscape for advanced healthcare management.



Join The Center for Biosimilars[®] network at centerforbiosimilars.com